Investing.com - Rhythm Pharma reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Rhythm Pharma announced earnings per share of $-0.79 on revenue of $4.28M. Analysts polled by Investing.com anticipated EPS of $-1.00 on revenue of $5.73M.
Rhythm Pharma shares are down 35% from the beginning of the year and are trading at $23.25 , down-from-52-week-high.
Rhythm Pharma shares gained 1.95% in intra-day trade after the report.
Rhythm Pharma follows other major Healthcare sector earnings this month
Rhythm Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar